A Phase II Study of Omacetaxine Mepesuccinate for Patients With Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia After Failure of Hypomethylating Agents

American Journal of Hematology - United States
doi 10.1002/ajh.25318
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Transplantation for Myelodysplastic Syndrome in the Era of Hypomethylating Agents

Current Opinion in Hematology
Hematology
2012English

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities

Cancer
Cancer ResearchOncology
2009English

Combination Therapies of Hypomethylating Agents for Elderly Patients With Acute Myeloid Leukemia

Acta Haematologica Polonica
OncologyHematology
2018English

Heterogeneous Patterns of CEBP Mutation Status in the Progression of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia to Acute Myelogenous Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2005English

Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia, and Acute Myeloid Leukemia Associated With Complete or Partial Monosomy 7

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1999English

Hypomethylating Agents in Combination With Histone Deacetylase Inhibitors in Higher Risk Myelodysplastic Syndromes: Is There a Light at the End of the Tunnel?

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy